- Additional key data presented at the congress indicates how
HDx therapy enabled by Theranova dialyzer is helping
advance “green” nephrology
- In total, Baxter supported 17 clinical presentations to advance
scientific exchange at ASN: Kidney Week 2023
Baxter International Inc. (NYSE:BAX), a global innovator in
kidney care and vital organ support, announced today new data
indicating Baxter’s Sharesource remote patient management
(RPM) digital platform, when used with an automated peritoneal
dialysis (PD) system, is associated with a 77% reduction in risk of
PD technique failure. Technique failure can be due to several
factors and results in PD patients being switched to in-center
dialysis. Additional key data show HDx therapy enabled by
Theranova dialyzer provides expanded hemodialysis therapy,
which can help reduce annual water consumption by 27% and annual
electricity usage by 17%, and associated costs, in comparison with
online HDF (hemodiafiltration).
The highlighted data was presented at ASN: Kidney Week, November
2-5, in Philadelphia, Pa., from abstracts—“Role of Remote
Monitoring in Automated Peritoneal Dialysis: Impact in SONG-PD
(Standardized Outcomes in Nephrology-Peritoneal Dialysis) and
Results from RPM-APD Multicenter Study” [#SA-PO654] and “Comparison
of Utilities Consumption Between Different Modalities of In-Center
Haemodialysis” [#TH-PO291]—and were part of 17 scientific exchanges
supported by Baxter during the conference.
“These new data help us further understand the essential role
digital capabilities play in helping kidney patients stay on home
dialysis longer, and the potential to support more sustainable care
options,” said Professor Peter Rutherford, MB BS, PhD., head of
global medical affairs, Kidney Care, Baxter. “Supporting continued
research on proven technologies helps the collective efforts of
industry, healthcare providers and policymakers better understand
how to make meaningful advances toward increasing access to and
improvements in the care we provide.”
About Sharesource Data
Baxter’s Sharesource RPM platform is the first two-way,
digital health solution that enables healthcare professionals to
stay connected with their home dialysis patients. The new data
presented at Kidney Week 2023 comes from a prospective
observational multicenter cohort study that included 232
patients—176 were treated on APD with RPM, 56 were treated on APD
without RPM—across 16 hospitals, over 12 months in Spain. In
propensity matched patients, the use of Sharesource was
associated with a 77% reduction in risk of technique failure (HR
0.23 95% CI 0.06-0.83, p = 0.024).
This evidence supplements earlier studies indicating
Sharesource may reduce hospitalization rates by up to 39%
and hospitalization days by up to 54%,1 and is associated with a
significant increase in time patients stay on therapy, by 3.2
months over the first two years.2 The remote patient management
platform—which currently supports more than 63,000 PD patients
globally and has helped deliver more than 66 million treatments in
85 countries—allows healthcare providers to securely view their
patients’ recently completed home dialysis-related treatment data
that is automatically collected after each PD session. Healthcare
professionals can then act on this information by remotely
adjusting their patients’ home device settings without requiring
them to make unplanned trips to the clinic.
About HDx Therapy Data
The Theranova dialyzer was designed to deliver HDx
therapy, which filters a wider range of molecules from the blood
than traditional hemodialysis (HD) filters by targeting efficient
removal of large-middle molecules,3,4,5,6 allowing for filtration
closer to that of the natural kidney.7,8 Many of these large-middle
molecules have been linked to the development of inflammation,
cardiovascular disease, and other comorbidities in dialysis
patients.3,4,5,9
The new in-center HD utility consumption study modeled the water
consumption and electricity usage of high flux HD, HDx
therapy enabled by Theranova, and online HDF within a
dialysis unit in Saudi Arabia caring for 120 patients per year in
30 dialysis beds, running two shifts per day. Water consumption per
year with online HDF was 4.1 million liters, but consumption was
27% lower with the use of HDx therapy. Furthermore, data
indicate HDx therapy demonstrated 17% lower electricity and
associated costs. This important environmental benefit of
HDx therapy enabled by Theranova dialyzer adds to the
clinical benefits and ease of delivery of this therapy.
The new data is added to an already robust compendium of
clinical evidence that indicates HDx therapy enabled by
Theranova may reduce the total cost of care, primarily
driven by potential reduction of cardiovascular events, infections,
medication usage, all-cause hospitalizations, hospitalization rate
and length of stay.10,11,12,13,14,15
About Baxter
Every day, millions of patients, caregivers and healthcare
providers rely on Baxter's leading portfolio of diagnostic,
critical care, kidney care, nutrition, hospital and surgical
products used across patient homes, hospitals, physician offices
and other sites of care. For more than 90 years, we've been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers who make it happen.
With products, digital health solutions and therapies available in
more than 100 countries, Baxter's employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and follow us on
X/Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning
potential benefits associated with the Sharesource remote patient
management platform. The statements are based on assumptions about
many important factors, including the following, which could cause
actual results to differ materially from those in the
forward-looking statements: demand for and market acceptance for
new and existing products; product development risks; inability to
create additional production capacity in a timely manner or the
occurrence of other manufacturing or supply difficulties (including
as a result of natural disasters, public health crises and
epidemics/pandemics, regulatory actions or otherwise); satisfaction
of regulatory and other requirements; actions of regulatory bodies
and other governmental authorities; product quality, manufacturing,
sterilization, or supply, or patient safety issues; changes in law
and regulations; and other risks identified in Baxter's most recent
filing on Form 10-K and Form 10-Q and other SEC filings, all of
which are available on Baxter's website. Baxter does not undertake
to update its forward-looking statements.
Baxter, Sharesource, HDx and Theranova are registered trademarks
of Baxter International Inc.
1 Sanabria M, et al. Remote Patient Monitoring Program in
Automated Peritoneal Dialysis: Impact on Hospitalizations. Perit
Dial Int. 2019 Sep-Oct;39(5):472-478. doi: 10.3747/pdi.2018.00287.
Epub 2019 Jul 23. PMID: 31337698.
2 Sanabria et al., 2022. Int’l Journal of Nephrology.
2022; Article ID 8646775, doi:10.1155/2022/8646775.
3 Hutchison CA, et al. The Rationale for Expanded Hemodialysis
Therapy (HDx). Contrib Nephrol. 2017; 191:142-52.
4 Neirynck N, et al. An update on uremic toxins. Int Urol
Nephrol. 2013; 45:139-50.
5 Duranton F, et al. European Uremic Toxin Work Group. Normal
and pathologic concentrations of uremic toxins. J Am Soc Nephrol.
2012 Jul; 23(7):1258-70.
6 Rosner M, et al. Classification of Uremic Toxins and Their
Role in Kidney Failure. Clin J Am Soc Nephrol.
2021;16(12):1918-1928
7 Zweigart C, et al. Medium cut-off membranes – closer to the
natural kidney removal function. Int J Artif Organs. 2017;
40(7):328-334.
8 Boschetti-de-Fierro A, et al. MCO membranes: Enhanced
Selectivity in High-Flux Class. Scientific Reports 2015;
5:18448.
9 Ronco C, et al. The rise of Expanded Hemodialysis. Blood
Purif. 2017;44:I–VIII.. Doi: 10.1159/000476012.
10 Molano-Trivino A, Sanabria M, Vesga J, Buitrago G, Sanchez R,
Rivera A. Effectiveness of medium cut-off vs high flux dialyzers: a
propensity score matching cohort study. In Nephrol Dial Transport.
2021;36:486-U948.
11 Cozzolino M, Magagnoli L, Ciceri P, Conte F, Galassi A.
Effects of a medium cut-off (THERANOVA®) dialyser on haemodialysis
patients: a prospective, cross-over study. Clin. Kidney J.
2021;14(1):382-389.
12 Sanabria RM, Hutchison CA, Vesga, JI, Ariza JG, Sanchez R,
Suarez AM. Expanded Hemodialysis and Its Effects on
Hospitalizations and Medication Usage: A Cohort Study. Nephron.
2021;145(2):179-187.
13 Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An
initial evaluation of expanded hemodialysis on hospitalizations,
drug utilization, costs, and patient utility in Colombia. Ther
Apher Dial. 2021;25(5):621-627.
14 Hadad-Arrascue F, Nilsson LG, Rivera AS, Bernardo AA,
Cabezuelo Romero JB. Expanded hemodialysis as effective alternative
to on-line hemodiafiltration: A randomized mid-term clinical trial.
Ther Apher Dial. 2022;26(1):37-44.
15 Blackowicz MJ, Falzon L, Beck W, Tran H, Weiner DE. Economic
evaluation of expanded hemodialysis with the THERANOVA 400
dialyzer: A post hoc evaluation of a randomized clinical trial in
the United States. Hemodialysis International. 2022.
https://doi.org/10.1111/hdi.13015
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106914287/en/
Media Contact Jill Carey-Hargrave, (224) 948-5353
media@baxter.com
Investor Contact Clare Trachtman, (224) 948-3020
Baxter (NYSE:BAX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Baxter (NYSE:BAX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024